Insider · CIK 0001807359

Epperly Melissa B,

Reports to the SEC for 4 companies · LONDON

sec.gov

Transactions

Companies

Filings

CIK

0001807359

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-10-01	ROIVRoivant Sciences Ltd.S Sale	Director	SSale	−900 sh	$36.57	−$32.9K	14,954
2026-10-01	ROIVRoivant Sciences Ltd.M Exercise/Conversion	Director	MExercise/Conversion	+17.8K sh	$4.46	+$79.2K	32,704
2026-10-01	ROIVRoivant Sciences Ltd. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−17.8K sh	—	—	151,416
2026-10-01	ROIVRoivant Sciences Ltd.S Sale	Director	SSale	−16.9K sh	$36.08	−$608K	15,854
2026-09-16	ROIVRoivant Sciences Ltd. · Stock Option (Right to Buy)A Award	Director	AAward	+10.5K sh	—	—	10,531
2026-09-16	ROIVRoivant Sciences Ltd.A Award	Director	AAward	+5,054 sh	—	—	14,954
2026-09-15	ROIVRoivant Sciences Ltd.S Sale	Director	SSale	−600 sh	$40.38	−$24.2K	9,900
2026-09-15	ROIVRoivant Sciences Ltd.S Sale	Director	SSale	−4,338 sh	$39.65	−$172K	10,500
2026-09-10	ROIVRoivant Sciences Ltd.F Tax Payment	Director	FTax Payment	−2,179 sh	$40.94	−$89.2K	14,838
2026-07-17	ROIVRoivant Sciences Ltd.A Award	Director	AAward	+543 sh	—	—	17,017
2026-06-29	ROIVRoivant Sciences Ltd.M Exercise/Conversion	Director	MExercise/Conversion	+17.8K sh	$4.46	+$79.2K	34,224
2026-06-29	ROIVRoivant Sciences Ltd.S Sale	Director	SSale	−15K sh	$34.32	−$515K	19,222
2026-06-29	ROIVRoivant Sciences Ltd.S Sale	Director	SSale	−2,748 sh	$34.71	−$95.4K	16,474
2026-06-29	ROIVRoivant Sciences Ltd. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−17.8K sh	—	—	169,166
2026-06-18	NAUTNautilus Biotechnology, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+45K sh	—	—	45,000
2026-04-17	ROIVRoivant Sciences Ltd.A Award	Director	AAward	+670 sh	—	—	16,474
2026-03-16	ROIVRoivant Sciences Ltd.S Sale	Director	SSale	−41.9K sh	$28.68	−$1.2M	15,804
2026-01-20	ROIVRoivant Sciences Ltd.A Award	Director	AAward	+815 sh	—	—	57,719
2026-01-20	ROIVRoivant Sciences Ltd.F Tax Payment	Director	FTax Payment	−54 sh	$22.98	−$1,240.92	57,665
2025-10-20	ROIVRoivant Sciences Ltd.A Award	Director	AAward	+1,056 sh	—	—	56,904
2025-09-10	ROIVRoivant Sciences Ltd.A Award	Director	AAward	+14.5K sh	—	—	57,509
2025-09-10	ROIVRoivant Sciences Ltd. · Stock Option (Right to Buy)A Award	Director	AAward	+33.7K sh	—	—	33,726
2025-09-10	ROIVRoivant Sciences Ltd.J Other	Director	JOther	−1,661 sh	$13.77	−$22.9K	55,848
2025-07-17	ROIVRoivant Sciences Ltd.A Award	Director	AAward	+1,609 sh	—	—	42,985
2025-06-23	NAUTNautilus Biotechnology, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+45K sh	—	—	45,000
2025-04-17	ROIVRoivant Sciences Ltd.A Award	Director	AAward	+1,847 sh	—	—	41,376
2025-01-23	ROIVRoivant Sciences Ltd.F Tax Payment	Director	FTax Payment	−180 sh	$11.21	−$2,017.8	39,529
2025-01-23	ROIVRoivant Sciences Ltd.A Award	Director	AAward	+1,672 sh	—	—	39,709
2024-10-21	ROIVRoivant Sciences Ltd.A Award	Director	AAward	+1,613 sh	—	—	38,037
2024-09-12	ROIVRoivant Sciences Ltd.J Other	Director	JOther	−4,245 sh	$12.12	−$51.4K	36,424
2024-09-10	ROIVRoivant Sciences Ltd. · Stock Option (Right to Buy)A Award	Director	AAward	+27.9K sh	—	—	27,894
2024-09-10	ROIVRoivant Sciences Ltd.A Award	Director	AAward	+16.4K sh	—	—	40,669
2024-07-23	ROIVRoivant Sciences Ltd.A Award	Director	AAward	+1,702 sh	—	—	24,263
2024-06-14	NAUTNautilus Biotechnology, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+45K sh	—	—	45,000
2024-04-24	ROIVRoivant Sciences Ltd.A Award	Director	AAward	+1,146 sh	—	—	22,684
2024-04-24	ROIVRoivant Sciences Ltd.F Tax Payment	Director	FTax Payment	−123 sh	$10.90	−$1,340.7	22,561
2024-04-03	Kinnate Biopharma Inc.Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−20.3K sh	—	—	0
2024-04-03	Kinnate Biopharma Inc.Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−60.8K sh	—	—	0
2024-04-03	Kinnate Biopharma Inc.Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−20.3K sh	—	—	0
2024-04-03	Kinnate Biopharma Inc.Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−25K sh	—	—	0
2024-02-12	ZNTLZentalis Pharmaceuticals, Inc.S Sale	Chief Financial Officer	SSale	−2,573 sh	$11.44	−$29.4K	451,449
2024-02-02	ZNTLZentalis Pharmaceuticals, Inc.S Sale	Chief Financial Officer	SSale	−8,669 sh	$11.54	−$100K	454,022
2024-02-01	ZNTLZentalis Pharmaceuticals, Inc.A Award	Chief Financial Officer	AAward	+75K sh	—	—	462,691
2024-02-01	ZNTLZentalis Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+75K sh	—	—	75,000
2024-01-19	ROIVRoivant Sciences Ltd.A Award	Director	AAward	+1,207 sh	—	—	21,538
2023-10-16	ROIVRoivant Sciences Ltd.A Award	Director	AAward	+1,226 sh	—	—	20,331
2023-10-04	ZNTLZentalis Pharmaceuticals, Inc.S Sale	Chief Financial Officer	SSale	−888 sh	$19.91	−$17.7K	387,691
2023-10-04	ZNTLZentalis Pharmaceuticals, Inc.S Sale	Chief Financial Officer	SSale	−4,594 sh	$19.43	−$89.2K	388,579
2023-09-12	ROIVRoivant Sciences Ltd. · Stock Option (Right to Buy)A Award	Director	AAward	+26.6K sh	—	—	26,595
2023-09-12	ROIVRoivant Sciences Ltd.A Award	Director	AAward	+17.8K sh	—	—	19,105

Recent filings

Accepted (ET)
Oct 5 18:054
Epperly Melissa B,0001807359-26-000018
SEC(opens sec.gov)
Sep 184
Epperly Melissa B,0001807359-26-000016
SEC(opens sec.gov)
Sep 174
Epperly Melissa B,0001807359-26-000014
SEC(opens sec.gov)
Sep 144
Epperly Melissa B,0001807359-26-000012
SEC(opens sec.gov)
Jul 214
Epperly Melissa B,0001140361-26-029192
SEC(opens sec.gov)
Jul 14
Epperly Melissa B,0001807359-26-000010
SEC(opens sec.gov)
Jun 224
Epperly Melissa B,0001807359-26-000008
SEC(opens sec.gov)
Apr 214
Epperly Melissa B,0001807359-26-000006
SEC(opens sec.gov)
Mar 184
Epperly Melissa B,0001807359-26-000004
SEC(opens sec.gov)
Jan 224
Epperly Melissa B,0001140361-26-002085
SEC(opens sec.gov)
Oct 224
Epperly Melissa B,0001140361-25-038997
SEC(opens sec.gov)

Companies

Address

C/O ROIVANT SCIENCES LTD. 7TH FLOOR, 50 BROADWAY

LONDON, SW1H 0DB